<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03496142</url>
  </required_header>
  <id_info>
    <org_study_id>URO-03-2017</org_study_id>
    <nct_id>NCT03496142</nct_id>
  </id_info>
  <brief_title>Perineal Versus Rectal Approach for Prostate Biopsy to Prevent Iatrogenic Infections</brief_title>
  <acronym>PRAPI</acronym>
  <official_title>Perineal Versus Rectal Approach for Prostate Biopsy to Prevent Iatrogenic Infections</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institut Mutualiste Montsouris</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Institut Mutualiste Montsouris</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Retrospective reports from literature have shown a lower rate of infections for transperineal
      versus transrectal approach for prostate biopsies in the setting of prostate cancer
      suspicion.

      The aim of this study would be to compare in a prospective randomized trial the rate of
      infection with transperineal versus transrectal approach.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Retrospective reports from literature have shown a lower rate of infections for the
      transperineal versus transrectal approach for prostate biopsies in the setting of prostate
      cancer suspicion.

      Post-biopsy infection is becoming a more and more challenging situation due to the increase
      of incidence and development of antibiotic resistant germs.

      The aim of this study would be to compare in a prospective randomized trial the rate of
      infection with transperineal vs transrectal approach.

      Patient presenting an indication of prostate biopsy (PSA elevation, suspicious lesion at
      digital rectal, suspicious lesion on MRI) would be randomized 1:1 among transrectal vs
      transperineal biopsies.

      Post-biopsy infection would be monitored by systemic urine analysis at one, two and four
      weeks after procedure and in case of clinical symptoms.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">April 2018</start_date>
  <completion_date type="Anticipated">May 2020</completion_date>
  <primary_completion_date type="Anticipated">May 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Patients who will have prostate biopsy will be randomized 1:1 among transperineal or transrecal approach</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of post-biopsy infection from Baseline to four weeks after prostate biopsy</measure>
    <time_frame>Four weeks post-biopsy</time_frame>
    <description>Urinary infection will be assessed based on urinanalysis : 10^5 germs and 10^4 leucocytes minimum)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Presence of antibiotic resistant germ</measure>
    <time_frame>One week, two weeks and four weeks post-biopsy</time_frame>
    <description>Antibiotic resistant germ will be assessed on urinanalysis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Presence of complication post-biopsy : hematuria, urinary retention, rectoragy, any other complication</measure>
    <time_frame>One week, two weeks and four weeks post-biopsy</time_frame>
    <description>Presence of complication will be assessed during phone interview with the patient</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">340</enrollment>
  <condition>Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>Transperineal prostate biopsy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patient will have a transperineal prostate biopsy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Transrectal prostate biopsy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patient will have a transrectal prostate biopsy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Transperineal prostate biopsy</intervention_name>
    <description>Puncture of 12 to 30 percutaneous prostate core biopsies through the perineum with a transrectal ultrasound probe guidance. The procedure would be performed with the Artemis (Eigen) device allowing topographic recording of the puncture and MRI / ultrasound image fusion in order to target the MRI suspected lesion.</description>
    <arm_group_label>Transperineal prostate biopsy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Transrectal prostate biopsy</intervention_name>
    <description>Patient would undergo 12 to 30 transrectal prostate core biopsies through the rectum with a transrectal ultrasound probe guidance. The procedure would be performed with the Artemis (Eigen) device allowing topographic recording of the puncture and MRI / ultrasound image fusion in order to target the MRI suspected lesion.</description>
    <arm_group_label>Transrectal prostate biopsy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Indication of prostate biopsy

        Exclusion Criteria:

          -  No indication of prostate biopsy

          -  Impossibility for prostate biopsy (e.g. major anal stenosis or history of anal
             amputation)

          -  Antibiotic treatment within three months before prostate biopsy
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alexandre INGELS, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institut Mutualiste Montsouris</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Alexandre INGELS, MD</last_name>
    <phone>0156616631</phone>
    <email>alexandre.ingels@imm.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Institut Mutualiste Montsouris</name>
      <address>
        <city>Paris</city>
        <zip>75014</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Alexandre INGELS, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 5, 2018</study_first_submitted>
  <study_first_submitted_qc>April 5, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">April 12, 2018</study_first_posted>
  <last_update_submitted>April 5, 2018</last_update_submitted>
  <last_update_submitted_qc>April 5, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 12, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Prostate biopsy approach</keyword>
  <keyword>Transrectal prostate biopsy</keyword>
  <keyword>Transperineal prostate biopsy</keyword>
  <keyword>Iatrogenic infection</keyword>
  <keyword>Prevention</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

